Lopes et al., 2018 - Google Patents
Phage display: an important tool in the discovery of peptides with anti-HIV activityLopes et al., 2018
- Document ID
- 7763137697211476722
- Author
- Lopes R
- Queiroz M
- Gomes S
- Vallinoto A
- Goulart L
- Ishak R
- Publication year
- Publication venue
- Biotechnology advances
External Links
Snippet
Human immunodeficiency virus (HIV) remains a worldwide health problem despite huge investments and research breakthroughs, and no single drug is effective in killing the virus yet. Among new strategies to control HIV infection, the phage display (PD) technology has …
- 238000002823 phage display 0 title abstract description 67
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lopes et al. | Phage display: an important tool in the discovery of peptides with anti-HIV activity | |
| Ensoli et al. | HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: A randomized phase II clinical trial | |
| WO2011043830A2 (en) | Methods, agents and peptides for inducing an innate immune response in hiv vaccination | |
| RU2603732C2 (en) | Rapid selection method for hiv gp-120 variants | |
| US9775895B2 (en) | HIV therapeutics and methods of making and using same | |
| Karpenko et al. | Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12 | |
| Humbert et al. | Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing | |
| Charles-Niño et al. | Variable epitope libraries: New vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response | |
| Boucher et al. | Immune response and epitope mapping of a candidate HIV‐1 p17 vaccine HGP30 | |
| Pedroza-Roldan et al. | Variable epitope library-based vaccines: Shooting moving targets | |
| Lee et al. | A single point mutation in HIV-1 V3 loop alters the immunogenic properties of rgp120 | |
| Zhang et al. | Mimotopes selected by biopanning with high-titer HIV-neutralizing antibodies in plasma from Chinese slow progressors | |
| US10125173B2 (en) | HIV-1 V3 mimotopes capable of inducing cross-clade neutralizing antibodies | |
| US20060275309A1 (en) | Peptide oligomers for use as hiv vaccines | |
| Ranga et al. | HIV/AIDS research in India: past, present and future | |
| Begum et al. | New approach for generation of neutralizing antibody against human T-cell leukaemia virus type-I (HTLV-I) using phage clones | |
| Garrett | Development and application of a phage-based deep mutational scanning system for mapping the fine epitopes of HIV-1 and SARS-CoV-2 specific antibodies | |
| US20140335119A1 (en) | POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL | |
| US10273292B2 (en) | Non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection | |
| WO2025030140A1 (en) | Modulation of hiv viral load by antibodies present prior to infection | |
| Nyombi | Evolution of HIV-1 in northern Tanzania: a retrospective study | |
| Misumi et al. | Proteomics of HIV-1 Virion | |
| Sankalé et al. | Virologic and Biologic Features of Human Immunodeficiency Virus Type 2 (HIV-2) | |
| Essomba | Genetic and immunological characterization of new subtype G envelope expressing HIV-1 pseudoviruses | |
| Bussolino et al. | Development of HIV-1 infectivity peptide inhibitor: A possible role of Tat in the virus entry process |